Algernon Health Inc. (AGW2)

Overview

Algernon Health Inc. is a clinical-stage biotechnology company that focuses on the development of repurposed therapeutic drugs. The company aims to address critical medical conditions, including non-alcoholic steatohepatitis (NASH), chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, stroke, and recovery from traumatic brain injuries. By advancing its lead drug candidates through off-label Phase II clinical trials in Canada and Australia, Algernon Health strives to offer innovative solutions to significant unmet medical needs. The company operates within the biotechnology and medical research sector, emphasizing novel drug repurposing strategies to enhance the pharmaceutical pipeline for complex diseases. Through its subsidiary, Algernon NeuroScience Inc., the company is also dedicated to the development of AP-188 as a potential treatment for stroke and brain trauma.

Products and Services

• NP-251 (Repirinast)

  This lead drug candidate is currently being evaluated in off-label Phase II clinical trials. NP-251 is being repurposed to target various serious medical conditions, providing hope for patients suffering from ailments such as chronic kidney disease and chronic cough.

• AP-188 (DMT)

  AP-188 is under development by Algernon NeuroScience Inc. as a potential therapeutic agent for stroke recovery and brain trauma. The compound is being repurposed to explore its efficacy in addressing neurological damage and enhancing recovery outcomes for affected patients.